Latest Capital Raises News

Felix Group Holdings has launched a $1 million Share Purchase Plan offering shares at a 3.7% discount to support its acquisition of Nexvia Pty Ltd and growth initiatives.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Vulcan Steel is set to acquire Roofing Industries for NZ$88 million, marking a strategic entry into New Zealand’s steel roofing market. The deal is backed by an A$87 million equity raise, positioning Vulcan for growth in building materials.

Vulcan Steel Limited reported a 10.9% revenue decline in FY25 alongside a 24.1% drop in adjusted EBITDA, while announcing a fully underwritten NZ$96 million equity raise to fund the acquisition of Roofing Industries Limited. The deal marks Vulcan’s strategic entry into the New Zealand steel roofing and cladding market with expected earnings accretion and no change to its dividend policy.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Miramar Resources has partnered with Sumitomo Metal Mining Oceania in a multi-million-dollar joint venture to explore for large-scale nickel-copper-platinum group element deposits at the Bangemall Projects in Western Australia.

Energy Transition Minerals Ltd has successfully raised $8 million through a heavily oversubscribed Share Purchase Plan, closing early due to strong shareholder demand. The funds will support the company’s critical minerals development strategy in Europe.

Acrow Limited reported a 23% revenue increase to $265.1 million for FY25, driven by strong growth in its Industrial Access division and key acquisitions. Despite a slight dip in earnings per share, the company declared a fully franked final dividend of 2.95 cents per share.

Activeport Group has successfully closed a fully underwritten rights issue, raising approximately $2.5 million to support its telecommunications software ambitions. The offer included free attaching options, signaling confidence in future growth.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Felix Group Holdings Ltd has announced a $1 million share purchase plan, offering eligible shareholders the chance to buy shares at $0.21 each starting 26 August 2025.